Related Experiment Video

Updated: Oct 1, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Concomitant beta-blocker therapy is associated with a lower occurrence of ventricular arrhythmias in patients with

Doron Aronson1, Andrew J Burger

  • 1Division of Cardiology, Rambam Medical Center, Haifa, Israel.

Journal of Cardiac Failure
|May 23, 2002
PubMed

Insights

Beta-blocker therapy significantly reduces ventricular arrhythmias in patients with decompensated heart failure. This finding suggests beta-blockers may prevent sudden cardiac death by suppressing dangerous heart rhythms.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Ventricular arrhythmias are common in advanced heart failure (CHF) and contribute to mortality.
  • Beta-blockers are hypothesized to reduce sudden death in CHF by suppressing these arrhythmias.
  • Data supporting this in decompensated CHF with neurohumoral activation is limited.

Purpose of the Study:

  • To investigate the effect of beta-blocker therapy on ventricular arrhythmias in patients hospitalized for decompensated congestive heart failure.

Main Methods:

  • Studied 236 patients with decompensated CHF, 50 on beta-blockers.
  • Assessed ventricular ectopy using 24-hour Holter monitoring.
  • Analyzed measures including premature ventricular beats (PVCs), couplets, and ventricular tachycardia.

Main Results:

  • Patients on beta-blockers showed significantly lower rates of ventricular ectopy.
  • Reductions observed: 15% in hourly PVCs, 75% in couplets, 72% in repetitive PVCs, 87% in ventricular tachycardia.
  • These reductions remained significant and independent in multivariate analysis.

Conclusions:

  • Concomitant beta-blocker use during heart failure decompensation is linked to reduced complex ventricular ectopy and ventricular tachycardia.
  • This anti-arrhythmic effect may offer protection against serious arrhythmias during heightened sympathetic activity in CHF.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.